SLC5A2 and chronic kidney disease: In fact, more recently, the DAPA-CKD trial confirmed these speculations by demonstrating that the SGLT2 inhibitor dapagliflozin significantly lowered the risk of glomerular filtration rate (GFR) decline, end-stage kidney disease, and death from renal cause in patients with CKD, regardless of their glycemic status (Heerspink et al., 2020).